Ongoing study
Official Study Title
BiomarkeR-guided EArly Clarithromycin Treatment to prevent sepsis progression in community-acquired pneumonia: The REACT Randomized clinical trial
Brief Description
The primary objective of the REACT RCT is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with CAP at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP.
Details
Status: Enrolment Completed – Analysis Pending
Study Type: Interventional (Clinical Trial)
Study phase: III
Study sites: 22 sites in Greece
Enrolled: 330 participants
ClinicalTrials.gov Identifier: NCT06294600
CT Number: 2023-507295-40-00
Start of trial: February 15th, 2024
End of trial: June 6th, 2026
Condition/Disease studied: CAP; Sepsis
Keywords: CAP; Clarithromycin; Sepsis; suPAR; PCT; ACCESS; SOFA; RSS
Connect to the REACT trial portal